CD19 and congenital rubella syndrome: We assessed the effect of GCs on CD19 and MSLN CAR T cells yet, the impact of GCs is context and dose-dependent and influences many cell subsets [32]; additional studies are therefore needed, for example on macrophages (paramount to CRS/ICANS development), to evaluate a more complete picture on the impact of GCs in the context of CAR T cell therapy [3].